Wockhardt's Zaynich, an investigational antibiotic, has been under evaluation for its efficacy in treating complicated ...

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...

In a retrospective, observational analysis, the authors found that empirical V- piperacillin-tazobactam was associated with a higher mortality than V-cefepime. V-piperacillin-tazobactam’s ...

Mumbai: Wockhardt has announced that Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 percent clinical efficacy in treating seriously ill patients with infections caused by ...

Wockhardt Limited announced that its innovative antibiotic, Zaynich (Zidebactam/Cefepime), demonstrated over 97% clinical efficacy in treating serious infections ...

Pursuant to Regulation 30 of SEBI Listing Regulations please find attached Press Release titled Zaynich(Zidebactum/Cefepime. WCK 5222)achieves over 97% Efficacy in Clinical Study for serious ...

Sensex Today | Stock Market LIVE Updates: The domestic benchmark indices Sensex and Nifty ended higher ahead of Union Budget on Saturday. Sensex rose 741 points or 0.97% to 77,500.57 while Nifty 50 ...

Among 2024’s notable new drugs were three approvals for antibiotic therapies: Allecra Therapeutics’ Exblifep (cefepime and enmetazobactam), Basilea Pharmaceutica’s Zevtera (ceftobiprole ...

Listen to Story New drug Zaynich has shown 97% effectiveness against multi-drug resistant infections It is currently nearing completion of a multi-national Phase III study Zaynich is a combination of ...

1 First Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang, China 2 Department of Infectious Diseases, The First Affiliated Hospital of Xiamen ...

"In a ground-breaking clinical study, Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97 per cent clinical efficacy in treating seriously ill patients with infections caused by ...

Expert Rev Anti Infect Ther. 2011;9(1):81-96. In summary, for empiric treatment of infections of the CNS following surgery and prophylactic antibiotics for trauma (Table 2) based on consensus ...